Science

Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

Francesco Soria/loop.frontiersin.org

Jan 22, 2025, 15:28

Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

European Urology Oncology shared an article by Francesco Soria on X:

“Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group by Francesco Soria, et al.”

Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration.

Authors: Francesco Soria, et al.

Clinical validation of the Intermediate-risk NMIBC Scoring System and Substratification Model

bladder cancer cancer Clinical validation European Urology Oncology fight against cancer Francesco Soria Global fight against cancer International Bladder Cancer Group NMIBC Non-muscle-invasive Bladder Cancer OncoDaily Oncology

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

Karen Knudsen: Clinical trials are the most advanced form of cancer care